Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018081521) SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/081521 International Application No.: PCT/US2017/058701
Publication Date: 03.05.2018 International Filing Date: 27.10.2017
IPC:
A61K 47/64 (2017.01) ,A61P 35/00 (2006.01) ,C07K 14/72 (2006.01)
[IPC code unknown for A61K 47/64]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
72
for hormones
Applicants:
TARVEDA THERAPEUTICS, INC. [US/US]; 134 Coolidge Avenue Watertown, Massachusetts 02472, US
Inventors:
SHINDE, Rajesh R.; US
ALARGOVA, Rossitza G.; US
LIM SOO, Patrick; US
SWERYDA-KRAWIEC, Beata; US
ALLAND, Leila; US
SEARS, Chris; US
Agent:
WARD, Donna T.; US
ZHU, Heng; US
Priority Data:
62/414,48128.10.2016US
Title (EN) SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
(FR) CONJUGUÉS CIBLANT LES SSTR, PARTICULES ET FORMULATIONS DE CEUX-CI
Abstract:
(EN) Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
(FR) L'invention concerne des conjugués d'un agent actif tel que le DM1, fixés à un fragment de ciblage, tel qu'un fragment de liaison du récepteur de la somatostatine, par l'intermédiaire d'un liant, et des particules comprenant de tels conjugués. Ces conjugués et particules peuvent fournir une meilleure administration spatiotemporelle de l'agent actif, une biodistribution et une pénétration dans la tumeur améliorées, et/ou une toxicité réduite. L'invention concerne également des procédés de fabrication des conjugués, des particules et de leurs formulations. L'invention porte en outre sur des procédés d'administration des formulations à un sujet en ayant besoin, par exemple, pour traiter ou prévenir le cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)